CL2024002839A1 - Inmunosupresión específica del antígeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1 - Google Patents

Inmunosupresión específica del antígeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1

Info

Publication number
CL2024002839A1
CL2024002839A1 CL2024002839A CL2024002839A CL2024002839A1 CL 2024002839 A1 CL2024002839 A1 CL 2024002839A1 CL 2024002839 A CL2024002839 A CL 2024002839A CL 2024002839 A CL2024002839 A CL 2024002839A CL 2024002839 A1 CL2024002839 A1 CL 2024002839A1
Authority
CL
Chile
Prior art keywords
diabetes
mhc
type
new treatment
specific immunosuppression
Prior art date
Application number
CL2024002839A
Other languages
English (en)
Spanish (es)
Inventor
Wischhusen Jörg
Bruttel Valentin
Brünnert Daniela
Ahsan Fadhil
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Publication of CL2024002839A1 publication Critical patent/CL2024002839A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
CL2024002839A 2022-03-24 2024-09-23 Inmunosupresión específica del antígeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1 CL2024002839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22164163 2022-03-24

Publications (1)

Publication Number Publication Date
CL2024002839A1 true CL2024002839A1 (es) 2025-02-21

Family

ID=81327177

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002839A CL2024002839A1 (es) 2022-03-24 2024-09-23 Inmunosupresión específica del antígeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1

Country Status (12)

Country Link
US (1) US20250205323A1 (https=)
EP (1) EP4499133A1 (https=)
JP (1) JP2025510149A (https=)
KR (1) KR20240167684A (https=)
CN (1) CN118922202A (https=)
AU (1) AU2023238308A1 (https=)
CA (1) CA3255483A1 (https=)
CL (1) CL2024002839A1 (https=)
CO (1) CO2024012945A2 (https=)
IL (1) IL315756A (https=)
MX (1) MX2024011668A (https=)
WO (1) WO2023180547A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3400069A4 (en) * 2016-01-04 2019-09-25 Cour Pharmaceuticals Development Company Inc. Particles for the Encapsulation of Fusion Proteins with Bundled Epitopes
EP3630809A1 (en) 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation

Also Published As

Publication number Publication date
WO2023180547A1 (en) 2023-09-28
EP4499133A1 (en) 2025-02-05
JP2025510149A (ja) 2025-04-14
IL315756A (en) 2024-11-01
CA3255483A1 (en) 2023-09-28
CO2024012945A2 (es) 2024-10-31
CN118922202A (zh) 2024-11-08
AU2023238308A1 (en) 2024-10-10
MX2024011668A (es) 2024-09-27
KR20240167684A (ko) 2024-11-27
US20250205323A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
JOP20230167A1 (ar) مساعدات مستقبل gpcr، وتركيبات صيدلانية تشتمل عليها، وطرق استخدامها
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
MX2019015742A (es) Receptores de celulas t novedosos, e inmunoterapia usando los mismos.
CL2020002574A1 (es) Análogos novedosos de glp-1
CO2020013221A2 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
MX2022014082A (es) Secuencias de interleucina (il-2) y usos de las mismas.
ECSP20082338A (es) Receptores del factor de crecimiento quimérico
CL2024001738A1 (es) Vacunas peptídicas
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
CL2024002724A1 (es) Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson
CO2024012332A2 (es) Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo
CO2024013220A2 (es) Inmunosupresión específica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis múltiple y la enfermedad por anticuerpos mog
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
UY38050A (es) Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas
CL2024002839A1 (es) Inmunosupresión específica del antígeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1
CL2025001142A1 (es) Anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, métodos terapéuticos y sus usos
BR112021021210A2 (pt) Conjunto de polipeptídeos, método para gerar um polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico, segundo polipeptídeo precursor heterodimérico e composição farmacêutica
CO2025009946A2 (es) Proteínas de unión al antígeno anti-tnfr2 y sus usos
PE20211772A1 (es) Inmunoterapia con peptidos restringidos a b 08 y una combinacion de peptidos contra el cancer y metodos relacionados
CO2025006863A2 (es) Métodos para el tratamiento de la obesidad
AR051928A1 (es) Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas
MX2024014378A (es) Proteinas de fusion que comprenden un agonista mejorado del receptor glp-1 y sus usos
AR053263A1 (es) Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologico
PE20080674A1 (es) Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico